Aushon BioSystems has partnered with LightArray Biotech to provide Aushon's suite of multiplex biomarker products and services to pharmaceutical, biotechnical, and academic research institutions in China, the Billerica, Mass.-based firm said this week.
Based in Shanghai, LightArray operates a drug development services laboratory in nearby Wuxi, and will now provide local researchers with protein biomarker testing based on Aushon's protein biomarker platforms.
According to Aushon, its menu includes more than 300 validated arrays, a multiplex biomarker sample testing service, protein biomarker kits, custom array and assay development, and array imaging and analysis systems.
Aushon CEO Pete Honkanen in a statement called the partnership with LightArray "strategic" and said it "enables companies located in China and involved in pre-clinical and clinical research to take advantage" of the firm's products and services.
LightArray CEO Alan Zhang said in a statement that the "adoption of biomarkers as a critical research tool in preclinical and clinical studies is growing rapidly in China," and LightArray's ability to provide regional access to Aushon's products and services will be "vital."
Financial details were not discussed.